Copertina

Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yun Wang, Yajing Wang, Yiming Mu, Yu Cheng
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Diabetes, Obesity and Metabolism
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study
di: Tatsuhiko Azegami, et al.
Pubblicazione: (2025)

Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
di: Chi‐Ho Lee, et al.
Pubblicazione: (2024)

Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis
di: Anat Tsur, et al.
Pubblicazione: (2025)

Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria
di: Afif Nakhleh, et al.
Pubblicazione: (2024)

Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes
di: Jingchuan Guo, et al.
Pubblicazione: (2024)

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
di: Hannah Wallace, et al.
Pubblicazione: (2025)

Nomogram‐based prediction of hypoglycemia risk in elderly community‐dwelling patients with type 2 diabetes: Development and validation in a multicentre real‐world cohort
di: Lingxue Chen, et al.
Pubblicazione: (2025)

The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
di: Mario Luca Morieri, et al.
Pubblicazione: (2026)

One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
di: Louise A. Donnelly, et al.
Pubblicazione: (2025)

Triple oral therapy with metformin, DPP ‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
di: Miao Yu, et al.
Pubblicazione: (2025)

Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors
di: Anat Tsur, et al.
Pubblicazione: (2025)

Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
di: Christina Baechle, et al.
Pubblicazione: (2024)

Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
di: Gregor A. Maier, et al.
Pubblicazione: (2026)

Individual treatment effects of sodium‐glucose co‐transporter‐2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real‐world data
di: Sukanya Siriyotha, et al.
Pubblicazione: (2024)

Integrative metabolomic and proteomic analysis of diabetic kidney disease progression with younger‐onset type 2 diabetes
di: Resham Lal Gurung, et al.
Pubblicazione: (2025)

SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany
di: Theresia Sarabhai, et al.
Pubblicazione: (2025)

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia
di: Hussein ElBadawi, et al.
Pubblicazione: (2025)

Baseline and cumulative Chinese visceral adiposity index and diabetic kidney disease: A prospective cohort study
di: Ming Sun, et al.
Pubblicazione: (2025)

SGLT2 inhibitors are associated with a reduced incidence of atrial fibrillation in type 2 diabetes mellitus
di: Mark Luedde, et al.
Pubblicazione: (2025)

Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia
di: Kaori Ikeda, et al.
Pubblicazione: (2025)

Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study
di: Hsiao‐Ling Chen, et al.
Pubblicazione: (2024)

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
di: Changyuan Yang, et al.
Pubblicazione: (2026)

Slowing the progression of diabetic and non‐diabetic kidney disease: A summary of the current evidence base for sodium‐glucose co‐transporter‐2 inhibitors
di: Viktor Rotbain Curovic, et al.
Pubblicazione: (2024)

Impact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study
di: Lijun Zhao, et al.
Pubblicazione: (2024)

Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy
di: Frank M. Gao, et al.
Pubblicazione: (2025)

Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
di: Ryo Suzuki, et al.
Pubblicazione: (2025)

The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
di: Yiming Mu
Pubblicazione: (2024)

Clinical characteristics and outcomes of diabetes‐related ketoacidosis ( DKA ) in sodium‐glucose co‐transporter‐2 inhibitor ( SGLT2i ) users with type 2 diabetes
di: Angelica Sharma, et al.
Pubblicazione: (2025)

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study
di: Testimony Ipaye, et al.
Pubblicazione: (2026)

Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4
di: Vikas S. Sridhar, et al.
Pubblicazione: (2024)

Two years with GIOIA ‘Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes’: A prospective, multicentre, quasi‐experimental study on sodium‐glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors in diabetes clinical practice
di: Miriam Longo, et al.
Pubblicazione: (2024)

Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study
di: Rayaz A. Malik, et al.
Pubblicazione: (2024)

Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation
di: Myung Jin Kim, et al.
Pubblicazione: (2025)

Real‐world predictors of progression to type 2 diabetes among adults with prediabetes
di: Tyler Dunn, et al.
Pubblicazione: (2026)

Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
di: João Sérgio Neves, et al.
Pubblicazione: (2025)

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials
di: João Pedro Ferreira, et al.
Pubblicazione: (2025)

Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes
di: Jiaqiang Zhang, et al.
Pubblicazione: (2025)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
di: Sama M. Abdel‐Rahman, et al.
Pubblicazione: (2026)

Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection
di: Hsiao‐Wei Wang, et al.
Pubblicazione: (2025)

Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data
di: Alex E. Henney, et al.
Pubblicazione: (2024)